Stryker Corporation
SYK
$313.22
+2.11%
Stryker Corporation is a leading global medical technology company that designs, manufactures, and markets a diverse portfolio of medical equipment, instruments, consumable supplies, and implantable devices. It operates as a dominant player in the medical devices industry, holding a top-three position in reconstructive orthopedic implants and the leadership position in operating room equipment. The current investor narrative is shaped by its strategic growth through acquisitions, such as the recent purchase of Amplitude Vascular Systems to bolster its peripheral vascular portfolio, and the ongoing debate around its ability to sustain growth and margins in a competitive and potentially volatile healthcare market, as evidenced by recent price weakness relative to the broader market.…
SYK
Stryker Corporation
$313.22
Related headlines
Investment Opinion: Should I buy SYK Today?
Rating: Hold. The core thesis is that Stryker is a high-quality company caught in a valuation correction, making it unattractive for new money until the technical downtrend stabilizes or fundamentals reassert themselves more forcefully, despite analyst bullishness.
Supporting Evidence: The stock's forward P/E of 18.36x is reasonable for a market leader, but the elevated trailing P/E of 41.38x and PEG of 5.16 signal overvaluation relative to near-term growth. Revenue growth remains strong at 11.42% YoY, and profitability is excellent with a 65.22% gross margin and $4.28B in TTM FCF. However, these strengths are overshadowed by severe price action, with the stock down 21.78% over the past year and trading near its 52-week low.
Risks & Conditions: The two biggest risks are continued multiple compression and a failure to meet the high earnings growth implied by the forward P/E. This Hold would upgrade to a Buy if the stock establishes a technical base above support at $281 and the forward P/E compresses further towards 16x on sustained earnings growth. It would downgrade to a Sell if revenue growth decelerates below 8% or if the price breaks decisively below the $281 support level. The stock is currently fairly valued to slightly overvalued relative to its own lofty historical standards, but the sharp correction has improved the long-term risk/reward.
Sign up to view all
SYK 12-Month Price Forecast
Stryker presents a classic 'falling knife' scenario where deteriorating price momentum clashes with a fundamentally sound business. The neutral stance reflects the high uncertainty in timing a bottom. The key factors are the company's ability to convert its robust revenue growth and margins into the earnings acceleration required to justify its valuation. Confidence is medium due to the clear disconnect between price and fundamentals, but the technical picture is undeniably weak. The stance would upgrade to bullish on a confirmed technical reversal above $340 with volume, or if forward earnings estimates see meaningful upward revisions. It would turn bearish on a breakdown below $281 with a concomitant downgrade in growth expectations.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $407.19 and implied upside of +30.0% versus the current price.
Average Target
$407.19
16 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
16
covering this stock
Price Range
$251 - $407
Analyst target range
The stock is covered by 16 analysts, and the institutional ratings show a pattern of reiterated Buy or Outperform ratings from firms like Needham, BTIG, and Bernstein as recently as January 2026, indicating maintained bullish sentiment among followers. The average target price and implied upside are not provided in the data, but the high-low target range and recent rating actions suggest analysts see the recent weakness as an opportunity, with the acquisition news viewed as a strategic positive for long-term growth, though the wide dispersion in historical valuation multiples points to ongoing debate about the appropriate premium for the stock.
Bulls vs Bears: SYK Investment Factors
The investment debate for Stryker centers on a stark divergence between deteriorating price action and resilient fundamentals. The bear case, currently supported by stronger evidence from the market's vote, is driven by severe technical breakdown, high absolute valuation, and acute recent underperformance. The bull case rests on robust revenue growth, exceptional profitability, a fortress balance sheet, and analyst conviction. The single most important tension is whether the current price weakness represents a cyclical derating of a premium stock or a fundamental breakdown in the growth story. The resolution hinges on the company's ability to deliver the earnings acceleration implied by its forward P/E of 18.36x to justify its still-lofty trailing multiple.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 11.42% year-over-year to $7.17 billion, demonstrating robust demand for its medical devices despite market headwinds. This growth is supported by a diversified portfolio across Orthopaedics and MedSurg segments.
- Excellent Profitability & Cash Flow: The company maintains a high gross margin of 65.22% and generated $4.28 billion in TTM free cash flow. This strong cash generation provides ample liquidity for strategic acquisitions, like Amplitude Vascular Systems, and shareholder returns.
- Healthy Balance Sheet: With a debt-to-equity ratio of 0.66 and a current ratio of 1.89, Stryker's financial position is solid. This low leverage provides strategic flexibility and resilience in a volatile market environment.
- Analyst Bullish Sentiment: Coverage from 16 analysts shows a pattern of reiterated Buy/Outperform ratings from major firms like Needham and BTIG as recently as January 2026. This indicates institutional confidence in the long-term thesis despite recent price weakness.
Bearish
- Severe Technical Downtrend: The stock is down 21.78% over the past year, drastically underperforming the S&P 500's +25.19% gain. Trading at just 26% of its 52-week range near $306.76, it shows persistent negative momentum and investor pessimism.
- High Trailing Valuation: A trailing P/E of 41.38x is elevated both historically and relative to the broader market. This premium valuation leaves the stock vulnerable to multiple compression if earnings growth fails to meet high expectations.
- Recent Sharp Underperformance: The stock fell 10.10% in the past month and 16.20% over three months, with a relative strength of -15.70 points versus the S&P 500. This indicates a lack of near-term catalysts and significant selling pressure.
- Elevated PEG Ratio: The PEG ratio of 5.16 is extremely high, suggesting the stock's price already reflects many years of future growth. This makes it sensitive to any deceleration in its growth trajectory.
SYK Technical Analysis
The stock is in a pronounced downtrend, with the 1-year price change of -21.78% significantly underperforming the S&P 500's +25.19% gain. As of the latest close at $306.76, the price is trading at approximately 26% of its 52-week range ($281.00 to $404.87), positioning it much closer to its 52-week low, which suggests a potential value opportunity but also reflects significant negative momentum and investor pessimism. Recent short-term momentum remains weak, with the stock down -10.10% over the past month and -16.20% over the past three months, both figures starkly contrasting with the S&P 500's positive returns of +5.6% and +8.42%, respectively, indicating severe relative underperformance and a lack of near-term catalysts to arrest the decline. Key technical support is clearly defined at the 52-week low of $281.00, while resistance sits at the 52-week high of $404.87; a decisive break below support could trigger further selling, whereas a recovery above recent highs near $390 would be needed to signal a trend reversal. The stock's beta of 0.81 indicates it has been less volatile than the market during this downturn, but the significant 1-month relative strength reading of -15.70 points underscores its acute underperformance.
Beta
0.81
0.81x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$281-$405
Price range past year
Annual Return
-20.5%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | -8.8% | +4.0% |
| 3m | -15.2% | +8.2% |
| 6m | -14.0% | +11.5% |
| 1y | -20.5% | +24.3% |
| ytd | -10.0% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $7.17 billion representing an 11.42% year-over-year increase, and the business is diversified with Orthopaedics ($4.96B) and MedSurg ($4.56B) segments contributing nearly equally to the latest period's sales. Profitability is solid, with the company reporting net income of $849 million for Q4 2025, a net margin of 11.84%, and a strong gross margin of 65.22%, although operating income of $1.96 billion for the quarter translates to an operating margin of 27.35%, showing healthy conversion. The balance sheet and cash flow position is strong, evidenced by a manageable debt-to-equity ratio of 0.66, robust free cash flow of $4.28 billion on a TTM basis, and a current ratio of 1.89, indicating ample liquidity to fund operations, strategic acquisitions, and shareholder returns without excessive reliance on external financing.
Quarterly Revenue
$7.2B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The stock trades at a trailing P/E of 41.38x and a forward P/E of 18.36x; the significant gap implies the market expects substantial earnings growth in the coming year. Compared to sector averages, Stryker's trailing P/E of 41.38x is a premium to the broader market, but its forward P/E of 18.36x is more reasonable, suggesting the premium is predicated on the anticipated earnings acceleration and the company's high-quality, market-leading profile. Historically, the current trailing P/E of 41.38x is above the stock's own historical range observed over recent quarters, which has typically fluctuated between the high 20s and low 40s, indicating the market is still pricing in optimistic long-term expectations despite the recent sharp price correction.
PE
41.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 23x~78x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Stryker's primary financial risk is valuation compression, given its high trailing P/E of 41.38x and PEG ratio of 5.16, which demand sustained high growth. While the balance sheet is strong with a 0.66 debt-to-equity ratio, the company relies on strategic acquisitions (like Amplitude Vascular) for growth, integrating which carries execution risk. Furthermore, a net margin of 11.84%, while solid, could face pressure from rising input costs or pricing competition in its core orthopedic and surgical markets.
Market & Competitive Risks: The stock trades at a significant premium to the market, with a forward P/E of 18.36x that, while more reasonable, still embeds high expectations. Its beta of 0.81 suggests it is less volatile than the market, but the severe -46.97 relative strength over one year shows it is suffering from intense sector-specific selling. Competitive disruption from peers like Boston Scientific, regulatory headwinds on device pricing, and potential delays in elective surgical procedures pose external threats to growth forecasts.
Worst-Case Scenario: The worst-case scenario involves a combination of an earnings miss, a failed acquisition integration, and a broader sector derating. This could trigger a wave of analyst downgrades and a re-rating towards its historical valuation lows. The realistic downside is to the 52-week low of $281, which represents an 8.4% decline from the current price of $306.76. A more severe bear case, factoring in a growth scare, could see a drawdown approaching the stock's recent max drawdown of -29.97%, implying a potential loss of up to 30% from recent highs.
FAQ
The key risks are: 1) Valuation/Multiple Compression Risk: The high trailing P/E (41.38x) and PEG ratio (5.16) make the stock vulnerable if growth falters. 2) Technical & Momentum Risk: The stock is in a pronounced downtrend, underperforming the S&P 500 by 47 percentage points over the past year, which can become a self-fulfilling prophecy. 3) Competitive & Sector Risk: Intense competition in medical devices and potential regulatory or reimbursement headwinds could pressure pricing and margins. 4) Execution Risk: The company's growth strategy relies on acquisitions (like Amplitude Vascular), which carry integration and synergy realization risks.
The 12-month forecast for SYK is a range-bound consolidation with a neutral bias. The base case (60% probability) sees the stock trading between $320 and $360 as it digests its valuation and stabilizes, aligning with analyst expectations for steady execution. The bull case (25% probability) targets $380 to $405, requiring an earnings beat and a sector re-rating. The bear case (15% probability) could see a retest of the 52-week low at $281 if growth disappoints. The most likely scenario is the base case, predicated on the assumption that Stryker meets, but does not significantly exceed, current earnings estimates of ~$23.31 per share.
SYK's valuation presents a mixed picture, leaning towards fair value with a risk of overvaluation. Its trailing P/E of 41.38x is historically high and indicates the market has priced in several years of strong growth. However, its forward P/E of 18.36x is more reasonable and suggests the recent price drop has improved the forward-looking valuation. Compared to sector averages, it likely trades at a premium due to its market-leading position and consistent execution. The valuation implies the market expects robust earnings acceleration in the coming year to bridge the gap between the trailing and forward multiples.
SYK is a good stock for long-term, patient investors, but timing is critical. The company's fundamentals are strong with 11.4% revenue growth and excellent cash flow, but the stock is in a severe downtrend, down 21.8% over the past year. At a forward P/E of 18.4x, the valuation is more reasonable, but the high trailing P/E of 41.4x indicates significant earnings growth is already priced in. The biggest downside risk is a further de-rating if growth slows. It is a good buy for investors who believe in the long-term medical device thesis and are willing to average in, but not for short-term traders seeking momentum.
SYK is unequivocally suitable for long-term investment, not short-term trading. Its low beta of 0.81, modest dividend yield of 0.96%, and business model focused on multi-year innovation and acquisition cycles are hallmarks of a long-term holding. The current technical weakness and valuation uncertainty make it a poor candidate for short-term gains. Investors should have a minimum horizon of 3-5 years to allow for the operational story to unfold and for the market to recognize the underlying fundamental value. This timeframe would allow the company to integrate recent acquisitions and demonstrate the earnings growth implied by its forward multiple.
